Europe
  • /
  • Europe
  • Britain
  • France
  • Germany
  • Italy
  • Spain
  • Poland
  • Netherlands
  • Ukraine
  • Africa
  • World
    • Turkiye
    • Russia
    • Iran
    • Japan
    • Canada
    • Australia
    • Afrique
    • Europa
  • @
  • EU
  • Euro Zone
  • Europe
  • European Central Bank
  • European Commission
  • European Council
  • European Parliament
  • Eurovision
Europe
  • /
  • Europe
  • Britain
  • France
  • Germany
  • Italy
  • Spain
  • Poland
  • Netherlands
  • Ukraine
  • Africa
  • World
    • Turkiye
    • Russia
    • Iran
    • Japan
    • Canada
    • Australia
    • Afrique
    • Europa
  • @

Browsing Tag

PPF

4 posts
EEU
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
Read More

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

  • July 17, 2026
Boehringer Ingelheim Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Not intended for UK and US audiences JASCAYD® (nerandomilast) is the…
EEuropean Commission
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
Read More

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

  • July 17, 2026
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the…
EEU
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
Read More

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

  • July 17, 2026
Boehringer Ingelheim Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Not intended for UK and US audiences JASCAYD® (nerandomilast) is the…
EEU
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Read More

European Commission approves JASCAYD®, bringing

  • July 17, 2026
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the…
Europe
www.europesays.com